EPISODE · Oct 14, 2024 · 6 MIN
Atrial fibrillation and semaglutide efficacy in obesity-related heart failure with preserved ejection fraction: STEP-HFpEF Program
from JACC This Week
In this episode, Dr. Valentin Foster highlights the October 2024 issue of JACC, which delves into the benefits of semaglutide for obesity-related heart failure with preserved ejection fraction. A key study presented shows that semaglutide significantly improves heart failure symptoms and physical limitations, particularly in patients with a history of atrial fibrillation, underscoring its efficacy beyond mere weight loss.
NOW PLAYING
Atrial fibrillation and semaglutide efficacy in obesity-related heart failure with preserved ejection fraction: STEP-HFpEF Program
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 3, 2026 ·44m
Feb 21, 2026 ·30m
Jan 2, 2026 ·47m